Bone Biologics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Bone Biologics.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Bone Biologics.

Recommendation Trends

Rating	Jan '23	Feb '23	Mar '23
Strong Buy	1	1	1
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Constantine Davides EF Hutton	EF Hutton	Strong Buy Reiterates $3,240	Strong Buy	Reiterates	$3,240	+265,473.77%	Apr 13, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Reiterates $3,240	Strong Buy	Reiterates	$3,240	+265,473.77%	Apr 3, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Initiates $3,240	Strong Buy	Initiates	$3,240	+265,473.77%	Oct 18, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.39

from -2.65

EPS Next Year

n/a

from -1.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
EPS	-	-	-204.05	-28.97	-2.65	-1.39
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026
High	-1.43
Avg	-1.39
Low	-1.33

EPS Growth

EPS Growth	2026
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.